| [1] |
Yao X, Song ZQ, Li W, et al. Guidelines for diagnosis and treatment of atopic dermatitis in China (2020)[J]. Int J Dermatol Venerol, 2021, 4(1): 1⁃9. DOI: 10.1097/jd9.00000000 00000143.
|
| [2] |
Moreno MA. JAMA pediatrics patient page. Atopic diseases in children[J]. JAMA Pediatr, 2016,170(1):96. DOI: 10.1001/jamapediatrics.2015.3886.
|
| [3] |
中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识[J]. 中华皮肤科杂志, 2023,56(1):5⁃15. DOI: 10. 35541/cjd.20220618.
|
| [4] |
Bieber T. The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification[J]. Ann Allergy Asthma Immunol, 2025,134(2):144⁃150. DOI: 10.1016/j.anai.2024.09.022.
|
| [5] |
Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges[J]. Nat Rev Drug Discov, 2023,22(8):662⁃680. DOI: 10.1038/s41573⁃023⁃00735⁃0.
|
| [6] |
Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease⁃modifying strategy[J]. Allergy, 2012,67(8):969⁃975. DOI: 10.1111/j.1398⁃9995.2012.02845.x.
|
| [7] |
Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis[J]. J Eur Acad Dermatol Venereol, 2024,38(5):e424⁃e427. DOI: 10.1111/jdv.19652.
|
| [8] |
Boesch M, Baty F, Rassouli F, et al. What is disease modification and is this concept even helpful?[J]. Eur J Intern Med, 2024,124:1⁃4. DOI: 10.1016/j.ejim.2024.03.025.
|
| [9] |
Hultsch T. The long road to atopic disease modification in infants with atopic dermatitis[J]. J Eur Acad Dermatol Venereol, 2024,38(4):627⁃628. DOI: 10.1111/jdv.19815.
|
| [10] |
Ong PY. Atopic dermatitis: is innate or adaptive immunity in control? A clinical perspective[J]. Front Immunol, 2022,13:943640. DOI: 10.3389/fimmu.2022.943640.
|
| [11] |
Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti⁃thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial[J]. J Am Acad Dermatol, 2019,80(4):1013⁃1021. DOI: 10.1016/j.jaad.2018.11.059.
|
| [12] |
Chen Y, Gutowska⁃Owsiak D, Hardman CS, et al. Proof⁃of⁃concept clinical trial of etokimab shows a key role for IL⁃33 in atopic dermatitis pathogenesis[J]. Sci Transl Med, 2019,11(515):eaax2945. DOI: 10.1126/scitranslmed.aax2945.
|
| [13] |
Maurer M, Cheung DS, Theess W, et al. Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis[J]. J Allergy Clin Immunol, 2022,150(6):1517⁃1524. DOI: 10.1016/j.jaci.2022.08.015.
|
| [14] |
Silverberg JI, Mustapa MN, Reid F, et al. Efficacy and safety of tozorakimab in moderate⁃to⁃severe atopic dermatitis: a phase 2a randomized controlled trial (FRONTIER⁃2)[J]. J Eur Acad Dermatol Venereol, 2025,39(6):1126⁃1133. DOI: 10.1111/jdv. 20388.
|
| [15] |
Croft M, Esfandiari E, Chong C, et al. OX40 in the pathogenesis of atopic dermatitis⁃a new therapeutic target[J]. Am J Clin Dermatol, 2024,25(3):447⁃461. DOI: 10.1007/s40257⁃023⁃00838⁃9.
|
| [16] |
Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti⁃OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phaseⅡa randomized placebo⁃controlled trial[J]. Br J Dermatol, 2023,189(5):531⁃539. DOI: 10.1093/bjd/ljad240.
|
| [17] |
Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti⁃OX40 ligand antibody, in patients with moderate⁃to⁃severe atopic dermatitis[J]. J Allergy Clin Immunol, 2025,155(4):1264⁃1275. DOI: 10.1016/j.jaci. 2024.10.031.
|
| [18] |
Guttman⁃Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti⁃OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019,144(2):482⁃493.e7. DOI: 10.1016/j.jaci.2018.11.053.
|
| [19] |
Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate⁃to⁃severe atopic dermatitis[J]. J Allergy Clin Immunol Glob, 2024,3(1):100195. DOI: 10.1016/j.jacig.2023.100195.
|
| [20] |
Guttman⁃Yassky E, Simpson EL, Reich K, et al. An anti⁃OX40 antibody to treat moderate⁃to⁃severe atopic dermatitis: a multicentre, double⁃blind, placebo⁃controlled phase 2b study[J]. Lancet, 2023,401(10372):204⁃214. DOI: 10.1016/S0140⁃6736(22)02037⁃2.
|
| [21] |
de Oliveira HM, Ruelas MG, Diaz CAV, et al. Safety and efficacy of anti⁃ox40 therapies in atopic dermatitis: a systematic review and meta⁃analysis[J]. Dermatitis, 2025. DOI: 10.1089/derm.2025. 0057.
|
| [22] |
Guttman⁃Yassky E, Simpson E, Esfandiari E, et al. Rocatinlimab: a novel T⁃cell rebalancing therapy targeting the OX40 receptor in atopic dermatitis[J]. Dermatol Ther (Heidelb), 2025, 15: 3153⁃3171. DOI: 10.1007/s13555⁃025⁃01492⁃1.
|
| [23] |
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease[J]. Nat Rev Drug Discov, 2022,21(1):21⁃40. DOI: 10.1038/s41573⁃021⁃00266⁃6.
|
| [24] |
Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis[J]. Drugs, 2024,84(11):1379⁃1394. DOI: 10.1007/s40265⁃024⁃02095⁃4.
|
| [25] |
Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phaseⅢ trials (ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021,184(3):437⁃449. DOI: 10.1111/bjd. 19574.
|
| [26] |
Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial[J]. JAMA Dermatol, 2023,159(6):596⁃605. DOI: 10.1001/jamadermatol. 2023.0627.
|
| [27] |
Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate⁃to⁃severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial[J]. J Am Acad Dermatol, 2023,88(4):816⁃823. DOI: 10.1016/j.jaad.2022.11.047.
|
| [28] |
Simpson EL, Blauvelt A, Silverberg JI, et al. Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate⁃to⁃severe atopic dermatitis who do not achieve IGA 0/1[J]. Am J Clin Dermatol, 2024,25(1):139⁃148. DOI: 10.1007/s40257⁃023⁃00817⁃0.
|
| [29] |
Silverberg JI, Guttman⁃Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate⁃to⁃severe atopic dermatitis[J]. N Engl J Med, 2023,388(12):1080⁃1091. DOI: 10.1056/NEJMoa2206714.
|
| [30] |
Blauvelt A, Thyssen JP, Guttman⁃Yassky E, et al. Efficacy and safety of lebrikizumab in moderate⁃to⁃severe atopic dermatitis: 52⁃week results of two randomized double⁃blinded placebo⁃controlled phaseⅢ trials[J]. Br J Dermatol, 2023,188(6):740⁃748. DOI: 10.1093/bjd/ljad022.
|
| [31] |
Bakker DS, van der Wal MM, Heeb LEM, et al. Early and long⁃term effects of dupilumab treatment on circulating t⁃cell functions in patients with moderate⁃to⁃severe atopic dermatitis[J]. J Invest Dermatol, 2021,141(8):1943⁃1953. DOI: 10. 1016/j.jid.2021.01.022.
|
| [32] |
Callewaert C, Nakatsuji T, Knight R, et al. IL⁃4Rα blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis[J]. J Invest Dermatol, 2020,140(1):191⁃202. DOI: 10.1016/j.jid.2019.05.024.
|
| [33] |
Nettis E, Patella V, Lombardo C, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate⁃to⁃severe adult atopic dermatitis[J]. Allergy, 2020,75(10):2653⁃2661. DOI: 10. 1111/all.14338.
|
| [34] |
Cork MJ, Lockshin B, Pinter A, et al. Clinically meaningful responses to dupilumab among children aged 6 months to 5 years with moderate⁃to⁃severe atopic dermatitis who did not achieve clear or almost clear skin according to the investigator's global assessment: a post hoc analysis of a phase 3 trial[J]. Acta Derm Venereol, 2024,104:adv13467. DOI: 10.2340/actadv.v104.13467.
|
| [35] |
杨子靖, 陈利红, 阮叶平, 等. 度普利尤单抗治疗老年性特应性皮炎的疗效及安全性研究[J]. 中华皮肤科杂志, 2025,58(1):65⁃69. DOI: 10.35541/cjd.20240359.
|
| [36] |
Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta⁃analysis of the dupilumab atopic dermatitis database for incident allergic events[J]. J Allergy Clin Immunol, 2023,151(3):756⁃766. DOI: 10.1016/j.jaci.2022.08.026.
|
| [37] |
Zhang L, Zhang W, Xu Y, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of stapokibart in healthy volunteers and adult subjects with atopic dermatitis[J]. Adv Ther, 2024,41(7):2953⁃2965. DOI: 10.1007/s12325⁃024⁃02887⁃w.
|
| [38] |
Zhao Y, Zhang J, Yang B, et al. Efficacy and safety of CM310 in moderate⁃to⁃severe atopic dermatitis: a multicenter, randomized, double⁃blind, placebo⁃controlled phase 2b trial[J]. Chin Med J (Engl), 2024,137(2):200⁃208. DOI: 10.1097/CM9.000000000 0002747.
|
| [39] |
Zhao Y, Zhang L, Wu L, et al. Long⁃term efficacy and safety of stapokibart for moderate⁃to⁃severe atopic dermatitis: 52⁃week results from a phase 3 trial[J]. Allergy, 2025,80(5):1348⁃1357. DOI: 10.1111/all.16368.
|
| [40] |
Wang J, White J, Sansone KJ, et al. Rademikibart (CBP⁃201), a next⁃generation monoclonal antibody targeting human IL⁃4Rα: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis[J]. Clin Transl Sci, 2023,16(12):2614⁃2627. DOI: 10.1111/cts.13656.
|
| [41] |
Silverberg JI, Strober B, Feinstein B, et al. Efficacy and safety of rademikibart (CBP⁃201), a next⁃generation mAb targeting IL⁃4Rα, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP⁃201⁃WW001)[J]. J Allergy Clin Immunol, 2024,153(4):1040⁃1049. DOI: 10.1016/j.jaci.2023. 11.924.
|
| [42] |
Wynne CJ, Cole A, Lemech C, et al. Safety, pharmacokinetics and preliminary efficacy of IL4⁃Rα monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase i, randomized, two⁃part, double⁃blind, placebo⁃controlled, dose⁃escalation, first⁃in⁃human clinical study[J]. Dermatol Ther (Heidelb), 2023,13(10):2357⁃2373. DOI: 10.1007/s13555⁃023⁃01010⁃1.
|
| [43] |
Veverka KA, Thng STG, Silverberg JI, et al. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate⁃to⁃severe atopic dermatitis: a phase 1b, multiple⁃ascending dose study[J]. J Am Acad Dermatol, 2024,90(3):504⁃511. DOI: 10.1016/j.jaad.2023.10.026.
|
| [44] |
Cevikbas F, Ward A, Veverka KA. Eblasakimab, an anti⁃il‑13rα1 antibody, reduces atopy⁃associated serum biomarkers in moderate‑to‑severe atopic dermatitis[J]. BioDrugs, 2024,38(6):821⁃830. DOI: 10.1007/s40259⁃024⁃00685⁃y.
|
| [45] |
Almet AA, Yuan H, Annusver K, et al. A roadmap for a consensus human skin cell atlas and single⁃cell data standardization[J]. J Invest Dermatol, 2023,143(9):1667⁃1677. DOI: 10.1016/j.jid.2023.03.1679.
|